US FDA’s decision to allow pharmacists to prescribe Pfizer’s COVID-19 antiviral raises hopes and fears that the idea that could be applied more broadly post-pandemic.
Pharmacist prescribing of Pfizer Inc.’s oral COVID-19 treatment Paxlovid may be closely watched, like other pandemic-related innovations, for potential use after the pandemic to improve access to a number of treatments.
The US Food and Drug Administration on 6 July updated the Paxlovid (nirmatrelvir/ritonavir) emergency use authorization to allow pharmacists...
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
